WILMINGTON, DE — Inhibikase Therapeutics (Nasdaq: IKT) granted stock options covering 981,243 shares of common stock to seven newly hired non-executive employees under its 2026 Inducement Equity Plan, the company announced.
The equity awards, approved by the compensation committee of the company’s board of directors, were issued as employment inducements under Nasdaq Listing Rule 5635(c)(4), which permits equity grants to new hires outside of shareholder-approved compensation plans.
The options carry an exercise price of $2.03 per share, matching the company’s June 30 closing stock price. Each option has a 10-year term, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the terms of the inducement plan and individual award agreements.
Inhibikase is a clinical-stage biotechnology company developing therapies for cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). Its lead drug candidate, IKT-001, is being evaluated in the global Phase 3 IMPROVE-PAH trial, which the company said is actively enrolling patients at approximately 180 sites worldwide.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.